Effect of Fc-receptor modulation on mumps-virus-dependent lymphocyte-mediated cytotoxicity in vitro

Combination of Vaccine-Strain Measles and Mumps Viruses Enhances Oncolytic Activity against Human Solid Malignancies

Oncolytic measles and mumps viruses (MeV, MuV) have a potential for anti-cancer treatment. We examined the anti-tumor activity of MeV, MuV, and MeV-MuV combination (MM) against human solid malignancies (HSM). MeV, MuV, and MM targeted and significantly killed various cancer cell lines of HSM but not normal cells. MM demonstrated a greater anti-tumor effect and prolonged survival in a human prostate cancer xenograft tumor model compared to MeV and MuV. MeV, MuV, and MM significantly induced the expression of immunogenic cell death markers and enhanced spleen-infiltrating immune cells. In conclusion, MM combination significantly improves the treatment of human solid malignancies.

The role of serologically defined epitopes on mumps virus HN-glycoprotein in the induction of virus-dependent cell-mediated cytotoxicity. Analysis with monoclonal antibodies

The importance of virus structural proteins for the induction of virus-dependent cellular cytotoxicity (VDCC) was studied by means of monoclonal antibodies raised in mice against mumps virions. Antibodies against the viral glycoprotein bearing the haemagglutination and neuraminidase activities (HN) inhibited VDCC but not the natural cytotoxicity (NK) displayed by the lymphocytes in the absence of virus. Antibodies to the fusion factor, the membrane protein or the nucleoprotein were inactive. These results confirmed our previous conclusion, that the only viral component required for VDCC induction is the HN protein. To clarify the role of this protein in VDCC further, the inhibitory activity of 13 HN-specific monoclonals, all of IgG isotype and directed against 9 distinct determinants, was studied in detail. Seven antibodies reacting with 3 different determinants of the peptide moiety of the HN protein were strongly inhibitory. The remaining antibodies, specific for 5 additional peptide epitopes, had intermediate or weak inhibitory effects. One carbohydrate specific anti-HN antibody was inactive although its antigen-binding capacity was of the same magnitude as that of a good inhibitory antibody. The anti-HN antibodies inhibited VDCC regardless of their IgG subclass. Moreover, VDCC inhibition was not correlated with the capacity of the antibodies to inhibit haemagglutination, haemolysis, neuraminidase activity, or the infectivity of the virus. These results suggest that full expression of VDCC requires the interaction of more than one of the serologically defined structures of the HN polypeptide with virus receptors on the lymphocytes and probably also on the target cells. These structures may be different at least in part from those involved in other known biological activities of the virus. Treatment of lymphocytes with virus increases both the number of target-binding cells (TBC) and the number of cytotoxic effector cells. However, when treated under conditions which gave optimal VDCC inhibition, none of the inhibitory antibodies reduced the virus-mediated increase in TBC. This indicates either that the anti-HN antibodies decreased the efficiency of effector-target cell interaction necessary for VDCC induction, or that they blocked a post-binding step required for triggering of cytotoxicity.

Virus-dependent cellular cytotoxicity in vitro. Mechanisms of induction and effector cell characterization

When human peripheral blood lymphocytes were incubated with 51Cr-labelled tissue culture cells (T24 bladder carcinoma cells or Chang liver cells), their natural cytotoxicity (NK) usually stopped after 8 h of incubation. The 51Cr release induced by lymphocytes treated with small amounts of live or ultraviolet-inactivated mumps virus was strongly enhanced and lasted longer. When the lymphocytes were fractionated by Percoll gradient centrifugation, the highest NK activity was found in the low-density fraction enriched in large granular lymphocytes, whereas that of the T-cell-enriched high-density fractions was low. In contrast, the virus-dependent cellular cytotoxic (VDCC) activity was more evenly distributed between these fractions. However, there was a difference between the target cells in that the T24 cells were more susceptible to the cytotoxicity of lymphocytes in the high-density fractions than the Chang cells. Studies of Percoll fractions in the single-cell agarose assay showed that virus treatment increased the proportion of both target binding cells and killer cells in all fractions. Moreover, in the high-density fractions the increase in the number of killer cells was greater than that in binding cells, suggesting that the enhanced target cell killing induced by the virions reflected both increased binding and effector cell activation. Surface marker analysis of unfractionated lymphocytes indicated that the number of T3+ effector cells was greater than that of the HNK-1+ effector cells, regardless of whether the lymphocytes were treated with virus or not. However, for both NK and VDCC, the T3 to HNK-1 distribution ratio on the effector cells was 5-8:1 for T24 and 2:1 for Chang. Taken together, the results indicate that both NK and VDCC effector cells are phenotypically heterogeneous and that the target cells may play an active role in the recruitment of those effector cells that are most efficient in that system. The enhancement of lymphocyte cytotoxicity primarily reflects effector cell recruitment.

Mumps virus-induced enhancement of the in vitro cytotoxicity of cord blood lymphocytes

Purified lymphocytes from the umbilical cord of healthy donors (CBL) displayed lower natural cytotoxicity (NK) and antibody-dependent cellular cytotoxicity (ADCC) than peripheral blood (PBL) from adult donors. In contrast, CBL treated with small amounts of UV-inactivated or live mumps virions expressed the same level of enhanced cytotoxicity (virus-dependent cytotoxicity (VDCC)) against non-infected target cells as PBL. For individual CBL donors there was no correlation between the level of NK and VDCC, indicating involvement of partly distinct effector cell populations. The heterogeneity of the effector cells active in VDCC was confirmed by cell fractionation experiments. The major CBL effector cells in NK and ADCC were found in 'non-T' lymphocyte fractions and/or in fractions containing cells with high-avidity receptors for IgG. In contrast, CBL fractions consisting of about 100% lymphocytes bearing T-cell markers and depleted of Fc gamma R+ cells were strongly cytotoxic in VDCC when T24 cells (human bladder carcinoma) were the targets. With two other target cell types of similar susceptibility to VDCC, the cytotoxic activity of T-cell-containing fractions was less pronounced, indicating that the target cells play an active role in effector cell selection. The surface marker profiles of the VDCC effector cells were the same for CBL and adult PBL. Incubation of CBL with UV-inactivated virions usually gave no significant stimulation of DNA synthesis above that seen in virus-free controls. Taken together, our results suggest that neither specific recognition of viral antigen by T cells nor mitogenic effects of viral material are involved in VDCC generation.

The role of viral glycoproteins in mumps virus-mediated antibody-dependent cellular cytotoxity in vitro

Treatment of human peripheral blood lymphocytes with live or UV-inactivated mumps virions enhances antibody-mediated cellular cytotoxicity (ADCC), reflected by increased target cell lysis in a 51Cr-release assay or an increased number of plaque-forming cells on monolayers of bovine erythrocytes (Eb) in the presence of anti-Eb antibodies. Virus treatment of the Eb targets causes a similar enhancement. The role of viral glycoproteins in ADCC enhancement was investigated by using a panel of monoclonal antibodies raised in mice against mumps virions. Most of the lymphocytes bound mumps virions, as ascertained by indirect immunofluorescence. A high proportion of virus-treated lymphocytes also formed rosettes with Eb. Anti-HN antibodies inhibited rosetting to various degrees. Although antibodies with high haemagglutination inhibition titres were most efficient inhibitors, antibodies without this serological activity were also inhibitory. Anti-F antibodies were only weakly inhibitory, and anti-NP antibodies had no effect. Anti-HN antibodies also abrogated target cell lysis in the 51Cr-release assay and effector cell recruitment in the ADCC plaque assay by inhibiting virus-mediated Eb-lymphocyte interactions both at the target cell and at the effector cell level. Anti-F or anti-NP antibodies were only weakly or not at all inhibitory. The results suggest that virus-mediated enhancement of ADCC is caused by the HN glycoprotein, primarily (although perhaps not exclusively) by its improvement of the effector cell-target cell contacts necessary for the efficient execution of target cell lysis.

Sendai-virus-induced cell-mediated cytotoxicity in vitro. The role of viral glycoproteins in cell-mediated cytotoxicity

Treatment of peripheral blood lymphocytes from normal donors with small amounts of purified Sendai virions results in enhanced cellular cytotoxicity in vitro to uninfected tissue culture target cells (virus-dependent cellular cytotoxicity (VDCC)), without any obvious correlation to the natural cytotoxicity (NK) displayed by the lymphocytes in the absence of virus. Removal from the virions of the two surface components present in the viral envelope, the HN glycoprotein (gp 71), carrying haemagglutinating and neuraminidase activity, and the F glycoprotein (gp 49), carrying fusion activity, by treatment with pronase abrogated their capacity to induce VDCC. Similar results were obtained when virions lacking the HN glycoprotein after treatment with chymotrypsin were added to the lymphocytes. In contrast, treatment of the virus particles with trypsin, which removed the F glycoprotein, did not affect their capacity to induce VDCC. When the solubilized and separated peplomers were used for lymphocyte treatment, either alone or in combination, the purified HN glycoprotein had full capacity to induce VDCC, whereas the F glycoprotein was inactive. These results suggest that the HM peplomer is solely or primarily responsible for the cytolytic activity arising in non-sensitized lymphocytes when confronted with certain viruses.

Influence of IgG and IgM receptor triggering on human natural killer cell cytotoxicity measured on the level of the single effector cell

By using an agarose single cell cytotoxicity assay, in combination with rosetting with IgG- or IgM-coated ox red blood cells for detection of Fc receptors for IgG (Fc gamma R) or IgM (Fc muR), it was found that 60% of natural killer (NK) cells are Fc gamma R+ and 17% FcmuR+. This system was further used to investigate the consequence of FcmuR and FC gamma R triggering on NK killing as measured on the single effector cell level. It was found that stimulation of the Fc gamma R, but not the FCmuR, resulted in substantial NK inhibition. In order for NK cells to be inhibited by IgG-coated ox red blood cells, they must first be exposed to the IgG-containing complex prior to conjugation with the target. While exposure of the Fc gamma R to immune complexes can block up to 57% of NK activity, the particulate immune complexes do not interfere with binding of effector cells to targets. Modulation of Fc gamma R by capping at 37 degrees C does not interfere with the NK inhibition for up to 3 h, though after 20 h, when Fc gamma R+ cells are almost completely modulated, NK activity has fully returned. Although to a lesser extent, the soluble immune complex human transferrin-anti-transferrin also reduces NK cell activity when activating effector cell FC gamma R prior to target cell binding. Also, pretreatment of target cells with high concentrations of specific antibody toward membrane antigens can block NK activity while not inhibiting target cell binding as evidenced by anti-IgM IgG binding to Daudi cells. The regulatory influence of the Fc gamma R on the NK system is discussed in terms of other functions associated with this receptor and in terms of its possible biological significance.

Interaction of target cell-bound C3bi and C3d with human lymphocyte receptors. Enhancement of antibody-mediated cellular cytotoxicity

The occurrence and distribution of distinct receptors for three C3 fragments on purified human blood lymphocytes were studied by rosette formation. Indicator cells were bovine, chicken, or sheep erythrocytes (E) bearing up to 100,000 molecules of human C3b (EC3b) without antibody. EC3b was converted to C3bi-bearing-E (EC3bi) with purified C3b inactivator (factor I) and beta1H (factor H), and to C3d-bearing E (EC3d) by treatment of EC3bi with trypsin. Using bovine E (Eb) as indicators, approximately 11% of the lymphocytes bound EbC3b, 6% bound EbC3bi and 2% bound EbC3d. Fractionation of the lymphocytes by adsorption to monolayers of C3-fragment-bearing Eb or by rosetting indicated that most of the cells with receptors for C3b were distinct from those having receptors for C3bi and/or C3d. Cells from two lymphoblastoid cell lines (Raji and Daudi) formed strong rosettes with EC3b, which were weak. 51Cr-labeled E was used as a target in antibody, C3-fragment-bearing E was not lysed by the lymphocytes. However, at suboptimal concentrations of IgG enhancing capacity of the fragments occurred in the order of C3bi greater than C3d greater than C3b. In addition, C3-fragment-bearing cells inhibited the lysis of antibody-coated cells not concluded that target cell bound C3 fragments enhance ADCC by improving contact between target cells and those effector cells which have C3 receptors. Cell-bound C3 effector cells. It is proposed that certain lymphocytes are capable of interacting with C3bi in addition to C3b and C3d and that C3bi and C3d have a greater regulatory effect on their cytolytic function than C3b.